We have a long-standing program of pre-clinical breast cancer research within the Kolling Institute.
Our work mainly focuses on a specific type of breast cancer called triple-negative breast cancer. This typically affects women at a younger age. It is more difficult to treat and has less favourable outcomes than other types of breast cancer.
Our team is working to develop new ways to predict how the disease will progress and new drugs to overcome resistance to chemotherapy and radiotherapy. Our research is also aimed at developing new treatments to replace chemotherapy.
Emeritus Professor, Medicine,
Northern Clinical School,
Faculty of Medicine and Health
Fellow of the Australian Academy of Science
Fellow of the Australasian Association of Clinical Biochemists
Senior Research Assistant
Medical Oncology: Professor Fran Boyle, Mater Hospital and University of Sydney
Cancer Immunology: Dr Lisa Hedger, Faculty of Science, University of Technology, Sydney
Pharmacy: Dr Pegah Varamini, University of Sydney
Chemistry: Dr Markus Müllner, Professor Richard Payne, University of Sydney
Our research program in triple-negative breast cancer has three main aims:
Posted on: 04 March, 2022
Researchers from the Kolling Institute and Royal North Shore Hospital will help drive a new project ..... Read more
Category: Funding support, Research Excellence
Posted on: 28 February, 2022
The Cancer Council NSW today announced funding for a new stem cell team at the Kolling Institute to ..... Read more
Category: Funding support, Research Excellence
Posted on: 09 February, 2022
The Kolling is set to be one of the first institutes in New South Wales to introduce new world-leadi..... Read more
Category: Research Excellence, World-leading technology